• Travere Therapeutics director Roy D. Baynes sold 4,500 common shares on May 5 at USD 46.65.
• Transaction followed exercise of stock options for 4,500 shares at USD 18.27.
• Beneficial ownership stood at 37,500 common shares after transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001680739-26-000008), on May 06, 2026, and is solely responsible for the information contained therein.